DOI QR코드

DOI QR Code

Elevated Serum Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios Could be Useful in Lung Cancer Diagnosis

  • Kemal, Yasemin (Department of Medical Oncology, Faculty of Medicine, 19 Mayis Univercity) ;
  • Yucel, Idris (Department of Medical Oncology, Faculty of Medicine, 19 Mayis Univercity) ;
  • Ekiz, Kubilay (Department of Internal Medicine, Faculty of Medicine, 19 Mayis Univercity) ;
  • Demirag, Guzin (Department of Medical Oncology, Faculty of Medicine, 19 Mayis Univercity) ;
  • Yilmaz, Bahiddin (Department of Medical Oncology, Faculty of Medicine, 19 Mayis Univercity) ;
  • Teker, Fatih (Department of Medical Oncology, Faculty of Medicine, 19 Mayis Univercity) ;
  • Ozdemir, Meltem (Department of Internal Medicine, Faculty of Medicine, 19 Mayis Univercity)
  • Published : 2014.03.30

Abstract

Background: Lung cancer (LC) is still the primary cause of cancer deaths worldwide, and late diagnosis is a major obstacle to improving lung cancer outcomes. Recently, elevated preoperative or pretreatment neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and mean platelet volume (MPV) detected in peripheral blood were identified as independent prognostic factors associated with poor survival with various cancers, including colon cancer, esophageal cancer, gastric cancer and breast cancer. Objective: The aim of this study was to examine whether MPV, NLR and PLR could be useful inflammatory markers to differentiate lung cancer patients from healthy controls. An investigation was also made of the relationship between these markers and other prognostic factors and histopathological subgroups. Materials and Methods: Retrospectively eighty-one lung cancer patients and 81 age-sexes matched healthy subjects included into the study. Patients with hypertension, hematological and renal disease, heart failure, chronic infection, hepatic disorder and other cancer were excluded from the study. The preoperative or pretreatment blood count data was obtained from the recorded computerized database. Results: NLR and PLR values were significantly higher in the LC patients compared to the healthy subjects.( NLR: 4.42 vs 2.45 p=0.001, PLR: 245.1 vs 148.2 p=0.002) MPV values were similar in both groups (7.7 vs 7.8). No statistically significant relationship was determined between these markers (MPV, NLR and PLR) and histopathological subgroups and TNM stages. Conclusions: NLR and PLR can be useful biomarkers in LC patients before treatment. Larger prospective studies are required to confirm these findings.

Keywords

References

  1. Azab B, Bhatt VR, Phookan J et al (2012). Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol, 19, 217-24. https://doi.org/10.1245/s10434-011-1814-0
  2. Balkwill F, Mantovani A (2001). Inflammation and cancer: back toVirchow? Lancet, 357, 539-45. https://doi.org/10.1016/S0140-6736(00)04046-0
  3. Bambace NM, Holmes CE (2011). The platelet contribution to cancer progression. J Thromb Haemost, 9, 237-49. https://doi.org/10.1111/j.1538-7836.2010.04131.x
  4. Benoy I, Salgado R, Colpaert C, et al (2002). Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer, 2, 311-5. https://doi.org/10.3816/CBC.2002.n.008
  5. De Larco JE, Wuertz BRK, Furcht LT (2004). The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res, 10, 4895-900. https://doi.org/10.1158/1078-0432.CCR-03-0760
  6. Donnem T, Bremnes RM, Busund LT et al (2012). Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer. J Thorac Dis, 4, 212-3.
  7. Dvorak HF, Brown LF, Detmar M, et al(1995).Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol, 146, 1029-39.
  8. Fidler IJ (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer, 3, 453-8. https://doi.org/10.1038/nrc1098
  9. Groome PA, Bolejack V, Crowley JJ et al (2007). The IASLC Lung Cancer Staging Project: validation of the proposal for revision of the T, N and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol, 2, 694-705. https://doi.org/10.1097/JTO.0b013e31812d05d5
  10. Gwak MS, Choi SJ, Kim JA et al (2007). Effects of gender on white blood cell populations and neutrophil-lymphocyte ratio following gastrectomy in patients with stomach cancer. J Korean Med, 22, 104-8. https://doi.org/10.3346/jkms.2007.22.S.S104
  11. Hoang T, Xu R, Schiller JH et al (2005). Clinical model to predict survival in chemo-naive patients with advanced non-small cell lung cancer treated with third generation chemotherapy regimen based on eastern cooperative oncology group data. J Clin Oncol, 23, 175-83. https://doi.org/10.1200/JCO.2005.04.177
  12. Holmes CE, Levis JE, Ornstein DL (2009). Activated platelets enhance ovarian cell invasion in a cellular model of metastasis. Clin Exp Metastasis, 26, 653-61. https://doi.org/10.1007/s10585-009-9264-9
  13. Howlader N, Noone AM, Krapcho M, et al (2009). SEER Cancer Statistics Review 1975-2009 (Vintage: Populations), Bethesda, MD, National Cancer Institute.
  14. Jemal A, Bray F, Center MM et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  15. Kai H, Kitadai Y, Kodama M Cho S, Kuroda T, Ito M et al (2005). Involvement of proinflammatory cytokinesIL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res, 25, 709-13.
  16. Kaya V, Yildirim M, Demirpence O, Yildiz M, Yalcin AY (2013). Prognostic significance of basic laboratory methods in nonsmall- cell-lung cancer. Asian Pac J Cancer Prev, 14, 5473-6. https://doi.org/10.7314/APJCP.2013.14.9.5473
  17. Kilincalp S, Ekiz F, Basar O, et al (2013). Platelet volume could be possible biomarker in early diagnosis and monitoring of gastric cancer. Platelets, [Epub ahead of print].
  18. Lee Y, Kim SH, Han JY, et al (2012). Early neutrophil-tolymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. J Cancer Res Clin Oncol, 138, 2009-16. https://doi.org/10.1007/s00432-012-1281-4
  19. Mangalpally KK, Siqueiros-Garcia A, Vaduganathan M (2010). Platelet activation patterns in plateletsize sub-populations: differential responses to aspirin in vitro. J Thromb Thrombolysis, 30, 251-62. https://doi.org/10.1007/s11239-010-0489-x
  20. Mantovani A, Allavena P, Sica A, Ballkwill F (2008). Cancerrelated inflammation. Nature, 454, 436-44 https://doi.org/10.1038/nature07205
  21. Ohashi R, Takahashi K, Miura K et al (2006). Prognostic factors in patients with inoperable non-small cell lung cancer-an analysis of long-term survival patients. Gan To Kagaku Ryoho, 33, 1595-602.
  22. Petrie HT, Klassen LW, Kay HD(1985). Inhibition of human Cytotoxic T lymphocyte activity in vitro By autologous peripheral blood granulocytes. J Immunol, 134, 230-4.
  23. Sandler A, Gray R, Perry M, et al (2006). Paclitaxel-carboplatin alone or with bevacizumab in non-small cell lung cancer. NEJM, 355, 2542-50. https://doi.org/10.1056/NEJMoa061884
  24. Schreiber RD, Old LJ, Smyth MJ (2011). Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 331, 1565-70. https://doi.org/10.1126/science.1203486
  25. Sharaiha RZ, Halazun KJ, Mirza F, et al (2011). Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol, 18, 3362-9. https://doi.org/10.1245/s10434-011-1754-8
  26. Smith R, Bosonnet L, Raraty M, et al (2009). Preoperative plateletlymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg, 197, 466-72. https://doi.org/10.1016/j.amjsurg.2007.12.057
  27. Suzuki K, Kachala SS, Kadota K et al (2011). Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res, 17, 5247-56. https://doi.org/10.1158/1078-0432.CCR-10-2805
  28. Tanner NT, Sherman CA, Silvestri GA (2012). Biomarkers in the selection of maintenance therapy in nonsmall cell lung cancer. Transl Lung Cancer Res, 1, 96-8.
  29. Thavaramara T, Phaloprakarn C, Tangjitgamol S et al (2011). Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer. J Med Assoc Thai, 94, 871-7.
  30. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev, 14, 5237-42. https://doi.org/10.7314/APJCP.2013.14.9.5237
  31. Walsh SR, Cook EJ, Goulder F et al (2005). Neutrophillymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol, 91, 181-4. https://doi.org/10.1002/jso.20329
  32. Wiesner T, Bugl S, Mayer F, et al (2010). Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. Clin Exp Metastasis, 27, 141-9. https://doi.org/10.1007/s10585-010-9311-6

Cited by

  1. Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab? vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4781
  2. Prognostic Evaluation of Categorical Platelet-based Indices Using Clustering Methods Based on the Monte Carlo Comparison for Hepatocellular Carcinoma vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5721
  3. Mean Platelet Volume as a Prognostic Marker in Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Combined Chemotherapy vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6421
  4. Prognostic Model Built on Blood-based Biomarkers in Patients with Metastatic Colorectal Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7327
  5. Elevated Neutrophil-to-Lymphocyte Ratio in Squamous Cell Carcinoma of Larynx Compared to Benign and Precancerous Laryngeal Lesions vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7351
  6. Is MPV a Real Prognostic Indicator for Non-small Cell Lung Cancer? vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.8003
  7. Diagnostic and Prognostic Importance of the Neutrophil Lymphocyte Ratio in Breast Cancer vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10363
  8. Neutrophil to Lymphocyte Ratio - Not an Independent Prognostic Factor in Patients with the Myelodysplastic Syndrome vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10883
  9. Neutrophil-lymphocyte Ratio Findings and Larynx Carcinoma: a Preliminary Study in Turkey vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.351
  10. Relations of Platelet Indices with Endometrial Hyperplasia and Endometrial Cancer vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4905
  11. Advances in Optimal Detection of Cancer by Image Processing; Experience with Lung and Breast Cancers vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5613
  12. Evaluation of Platelet Indices in Lung Cancer Patients vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7599
  13. Value of the Platelet to Lymphocyte Ratio in the Diagnosis of Ovarian Neoplasms in Adolescents vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.2037
  14. Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio vol.18, pp.7, 2015, https://doi.org/10.1111/1756-185X.12582
  15. Diagnostic value of neutrophil-lymphocyte and albumin-globulin ratios in canine soft tissue sarcoma vol.57, pp.3, 2015, https://doi.org/10.1111/jsap.12435
  16. Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer pp.1792-1082, 2015, https://doi.org/10.3892/ol.2015.3783
  17. Mean platelet volume predicts chemotherapy response and prognosis in patients with unresectable gastric cancer pp.1792-1082, 2015, https://doi.org/10.3892/ol.2015.3784
  18. Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Poor Survival in Patients with Stage I-III Non-Small Cell Lung Cancer vol.11, pp.10, 2016, https://doi.org/10.1371/journal.pone.0163397
  19. Platelet–Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer vol.11, pp.7, 2016, https://doi.org/10.1371/journal.pone.0153459
  20. Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2860-6
  21. Lack of Variation in Inflammatory Hematological Parameters between Benign Nodular Goiter and Papillary Thyroid Cancer vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.2321
  22. Preoperative NLR and PLR in the middle or lower ESCC patients with radical operation vol.26, pp.2, 2016, https://doi.org/10.1111/ecc.12445
  23. Diagnostic and prognostic roles of the mean platelet volume in malignant tumors: a systematic review and meta-analysis vol.27, pp.8, 2016, https://doi.org/10.3109/09537104.2016.1169265
  24. The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic review vol.115, pp.4, 2017, https://doi.org/10.1002/jso.24523
  25. Platelet Distribution Width as a Predictor of Metastasis in Gastric Cancer Patients vol.48, pp.4, 2017, https://doi.org/10.1007/s12029-016-9886-5
  26. The prognostic value of preoperative inflammation-based prognostic scores and nutritional status for overall survival in resected patients with nonmetastatic Siewert type II/III adenocarcinoma of esophagogastric junction vol.96, pp.30, 2017, https://doi.org/10.1097/MD.0000000000007647
  27. Importance of laboratory parameters in patients with obstructive sleep apnea and their relationship with cardiovascular diseases pp.08878013, 2017, https://doi.org/10.1002/jcla.22199
  28. After neoadjuvant chemotherapy platelet/lymphocyte ratios negatively correlate with prognosis in gastric cancer patients pp.08878013, 2018, https://doi.org/10.1002/jcla.22364
  29. Mean platelet volume provides beneficial diagnostic and prognostic information for patients with resectable gastric cancer vol.12, pp.4, 2016, https://doi.org/10.3892/ol.2016.4913
  30. Pretreatment Inflammatory Indexes as Prognostic Predictors for Survival in Colorectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy vol.8, pp.1, 2018, https://doi.org/10.1038/s41598-018-21093-7
  31. Single and combined use of red cell distribution width, mean platelet volume, and cancer antigen 125 for differential diagnosis of ovarian cancer and benign ovarian tumors vol.11, pp.1, 2018, https://doi.org/10.1186/s13048-018-0382-3
  32. Relationship between Inflammatory and Biological Markers and Lung Cancer vol.7, pp.7, 2018, https://doi.org/10.3390/jcm7070160
  33. An inflammation-related nomogram for predicting the survival of patients with non-small cell lung cancer after pulmonary lobectomy vol.18, pp.1, 2018, https://doi.org/10.1186/s12885-018-4513-4
  34. Serum biomarkers in patients with stable and acute exacerbation of chronic obstructive pulmonary disease: A comparative study vol.0, pp.0, 2019, https://doi.org/10.2478/jomb-2018-0050